SSc in 2011: From mechanisms to medicines.
Where this comes from
- Record sourced from PubMed, PMID 22231235.
- Also identified by DOI 10.1038/nrrheum.2011.203.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Findings from ongoing studies of imatinib in systemic sclerosis (SSc) were eagerly awaited in 2011, but results from these clinical trials have so far been disappointing. However, progress in the understanding of the mechanisms that underlie SSc pathogenesis could provide clues to novel targets for 2012 and beyond.
Medical subject headings
- Fibrosis
- Molecular Targeted Therapy
- Piperazines
- Protein Kinase Inhibitors
- Pyrimidines
- Scleroderma, Systemic